▁women ▁are ▁already ▁being ▁gen ot yp ed ▁for ▁certain ▁mut ations ▁in ▁the ▁BR CA 1 ▁and ▁BR CA 2 ▁gene ▁if ▁they ▁are ▁pre dis posed ▁because ▁of ▁a ▁family ▁history ▁of ▁breast ▁cancer ▁or ▁o var ian ▁cancer . ▁As ▁more ▁causes ▁of ▁dise ases ▁are ▁mapped ▁out ▁according ▁to ▁mut ations ▁that ▁exist ▁within ▁a ▁gen ome , ▁the ▁easier ▁they ▁can ▁be ▁identified ▁in ▁an ▁individual . ▁Me asures ▁can ▁then ▁be ▁taken ▁to ▁prevent ▁a ▁disease ▁from ▁developing . ▁Even ▁if ▁mut ations ▁were ▁found ▁within ▁a ▁gen ome , ▁having ▁the ▁details ▁of ▁their ▁DNA ▁can ▁reduce ▁the ▁impact ▁or ▁delay ▁the ▁on set ▁of ▁certain ▁dise ases . ▁Having ▁the ▁gen etic ▁content ▁of ▁an ▁individual ▁will ▁allow ▁better ▁gu ided ▁dec isions ▁in ▁determ ining ▁the ▁source ▁of ▁the ▁disease ▁and ▁thus ▁tre ating ▁it ▁or ▁prevent ing ▁its ▁pro gression . ▁This ▁will ▁be ▁extremely ▁useful ▁for ▁dise ases ▁like ▁Al z heimer ’ s ▁or ▁can cers ▁that ▁are ▁thought ▁to ▁be ▁linked ▁to ▁certain ▁mut ations ▁in ▁our ▁DNA . ▁ ▁A ▁tool ▁that ▁is ▁being ▁used ▁now ▁to ▁test ▁effic acy ▁and ▁safety ▁of ▁a ▁drug ▁specific ▁to ▁a ▁target ed ▁patient ▁group / sub - group ▁is ▁companion ▁di agnostics . ▁This ▁technology ▁is ▁an ▁ass ay ▁that ▁is ▁developed ▁during ▁or ▁after ▁a ▁drug ▁is ▁made ▁available ▁on ▁the ▁market ▁and ▁is ▁helpful ▁in ▁en han cing ▁the ▁th era pe ut ic ▁treatment ▁available ▁based ▁on ▁the